Zobrazeno 1 - 10 of 13 pro vyhledávání: '"Komatsu SI"'
1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
6
Akademický článek
Effects of two weeks of food restriction on toxicological parameters in cynomolgus monkeys.
Autor: Fujisawa N; Translational Research Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan., Matsushita T; Translational Research Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan., Matsuo S; Translational Research Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan., Hiranuma M; Chugai Research Institute for Medical Science, Inc., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan., Azabu H; Chugai Research Institute for Medical Science, Inc., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan., Saito R; Translational Research Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan., Komatsu SI; Research Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan., Kato A; Translational Research Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan., Toyota N; Translational Research Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan., Taketo J; Translational Research Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan., Suzuki H; Translational Research Division, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan.
Publikováno v: Experimental animals [Exp Anim] 2024 Feb 14; Vol. 73 (1), pp. 73-82. Date of Electronic Publication: 2023 Aug 29.
Zobrazit plný text záznamu
7
Akademický článek
A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state.
Autor: Teranishi-Ikawa Y; Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Kanagawa, Japan., Soeda T; Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Kanagawa, Japan., Koga H; Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Kanagawa, Japan. Electronic address: koga.hikaru78@chugai-pharm.co.jp., Yamaguchi K; Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Kanagawa, Japan., Kato K; Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Kanagawa, Japan., Esaki K; Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Kanagawa, Japan., Asanuma K; Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Kanagawa, Japan., Funaki M; Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Kanagawa, Japan., Ichiki M; Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Kanagawa, Japan., Ikuta Y; Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Kanagawa, Japan., Ito S; Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Kanagawa, Japan., Joyashiki E; Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Kanagawa, Japan., Komatsu SI; Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Kanagawa, Japan., Muto A; Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Kanagawa, Japan., Nishimura K; Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Kanagawa, Japan., Okuda M; Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Kanagawa, Japan., Sanada H; Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Kanagawa, Japan., Sato M; Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Kanagawa, Japan., Shibahara N; Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Kanagawa, Japan., Wakabayashi T; Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Kanagawa, Japan., Yamaguchi K; Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Kanagawa, Japan., Matsusaki A; Translational Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan., Sampei Z; Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Kanagawa, Japan., Shiraiwa H; Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Kanagawa, Japan., Konishi H; Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Kanagawa, Japan., Kawabe Y; Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Kanagawa, Japan., Hattori K; Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Kanagawa, Japan., Kitazawa T; Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Kanagawa, Japan., Igawa T; Research Division, Chugai Pharmaceutical Co, Ltd, Yokohama, Kanagawa, Japan; Translational Research Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.
Publikováno v: Journal of thrombosis and haemostasis : JTH [J Thromb Haemost] 2024 Feb; Vol. 22 (2), pp. 430-440. Date of Electronic Publication: 2023 Nov 06.
Zobrazit plný text záznamu
8
Akademický článek
Determination of starting dose of the T cell-redirecting bispecific antibody ERY974 targeting glypican-3 in first-in-human clinical trial.
Autor: Komatsu SI; Discovery Pharmacology Department, Kamakura Research Division, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa, 247-8530, Japan., Kayukawa Y; Discovery Pharmacology Department, Kamakura Research Division, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa, 247-8530, Japan., Miyazaki Y; Discovery Pharmacology Department, Kamakura Research Division, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa, 247-8530, Japan., Kaneko A; Discovery Pharmacology Department, Kamakura Research Division, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa, 247-8530, Japan., Ikegami H; Discovery Pharmacology Department, Kamakura Research Division, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa, 247-8530, Japan., Ishiguro T; Translational Research Division, Chugai Pharmaceutical Co., Ltd., 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo, 103-8324, Japan., Nakamura M; Translational Research Division, Chugai Pharmaceutical Co., Ltd., 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo, 103-8324, Japan., Frings W; Discovery Pharmacology Department, Kamakura Research Division, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa, 247-8530, Japan., Ono N; Discovery Pharmacology Department, Kamakura Research Division, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa, 247-8530, Japan., Sakata K; Discovery Pharmacology Department, Kamakura Research Division, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa, 247-8530, Japan., Fujii T; Discovery Pharmacology Department, Kamakura Research Division, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa, 247-8530, Japan., Kishishita S; Translational Research Division, Chugai Pharmaceutical Co., Ltd., 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo, 103-8324, Japan., Kitazawa T; Discovery Pharmacology Department, Kamakura Research Division, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa, 247-8530, Japan., Endo M; Translational Research Division, Chugai Pharmaceutical Co., Ltd., 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo, 103-8324, Japan., Sano Y; Discovery Pharmacology Department, Kamakura Research Division, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa, 247-8530, Japan. sanoyuj@chugai-pharm.co.jp.
Publikováno v: Scientific reports [Sci Rep] 2022 Jul 19; Vol. 12 (1), pp. 12312. Date of Electronic Publication: 2022 Jul 19.
Zobrazit plný text záznamu
9
Akademický článek
Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly Effective In Vivo without Systemic Immune Activation.
Autor: Kamata-Sakurai M; Translational Research Division, Chugai Pharmaceutical Co., Ltd., Chuo-ku, Tokyo, Japan. mika.sakurai22@chugai-pharm.co.jp., Narita Y; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan., Hori Y; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Nemoto T; Translational Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan., Uchikawa R; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan., Honda M; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Hironiwa N; Chugai Pharmabody Research Pte. Ltd., Synapse, Singapore., Taniguchi K; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan., Shida-Kawazoe M; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Metsugi S; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan., Miyazaki T; Clinical Development Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan., Wada NA; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Ohte Y; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan., Shimizu S; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Mikami H; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Tachibana T; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Ono N; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan., Adachi K; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Sakiyama T; Pharmaceutical Technology Division, Chugai Pharmaceutical Co., Ltd., Kita-ku, Tokyo, Japan., Matsushita T; Translational Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Kadono S; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan., Komatsu SI; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Sakamoto A; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Horikawa S; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan., Hirako A; Translational Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Hamada K; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan., Naoi S; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Savory N; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Satoh Y; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan., Sato M; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Noguchi Y; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Shinozuka J; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Kuroi H; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Ito A; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Wakabayashi T; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Kamimura M; Chugai Research Institute for Medical Science, Inc., Kamakura, Kanagawa, Japan., Isomura F; Chugai Research Institute for Medical Science, Inc., Gotemba, Shizuoka, Japan., Tomii Y; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Sawada N; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan., Kato A; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Ueda O; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Nakanishi Y; Project & Lifecycle Management Unit, Chugai Pharmaceutical Co., Ltd., Chuo-ku, Tokyo, Japan., Endo M; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Jishage KI; Chugai Research Institute for Medical Science, Inc., Kamakura, Kanagawa, Japan.; Chugai Research Institute for Medical Science, Inc., Gotemba, Shizuoka, Japan., Kawabe Y; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Kitazawa T; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan., Igawa T; Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.; Research Division, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan.; Chugai Pharmabody Research Pte. Ltd., Synapse, Singapore.
Publikováno v: Cancer discovery [Cancer Discov] 2021 Jan; Vol. 11 (1), pp. 158-175. Date of Electronic Publication: 2020 Aug 25.
Zobrazit plný text záznamu
10
Akademický článek
Investigating toxicity specific to adjuvanted vaccines.
Autor: Matsumoto M; Review Division, Pharmaceuticals and Medical Devices Agency (PMDA)(1), Kasumigaseki 3-3-2, Chiyoda-ku, Tokyo 100-0013, Japan. Electronic address: matsumoto-mineo@pmda.go.jp., Komatsu SI; Product Development Division, POC Clinical Research Inc.(1), Akasaka 1-11-44, Minato-ku, Tokyo 107-0052, Japan., Ikeda T; Safety Assessment, MSD K.K.(1), Kudan-kita 1-13-12, Chiyoda-ku, Tokyo 102-8667, Japan., Shimomura K; Vaccine Research Laboratories, Kitasato Daiichi Sankyo Vaccine Co. Ltd.(1), Kita-Kasai 1-16-13, Edogawa-ku, Tokyo 134-8630, Japan., Watanabe K; Research Division, Chugai Pharmaceutical Co. Ltd.(1), Komakado, 1-135, Gotemba, Shizuoka 412-8513, Japan., Hirabayashi K; Review Division, Pharmaceuticals and Medical Devices Agency (PMDA)(1), Kasumigaseki 3-3-2, Chiyoda-ku, Tokyo 100-0013, Japan., Sawada JI; Review Division, Pharmaceuticals and Medical Devices Agency (PMDA)(1), Kasumigaseki 3-3-2, Chiyoda-ku, Tokyo 100-0013, Japan., Maki K; Review Division, Pharmaceuticals and Medical Devices Agency (PMDA)(1), Kasumigaseki 3-3-2, Chiyoda-ku, Tokyo 100-0013, Japan., Shinoda K; Review Division, Pharmaceuticals and Medical Devices Agency (PMDA)(1), Kasumigaseki 3-3-2, Chiyoda-ku, Tokyo 100-0013, Japan., Fueki O; Review Division, Pharmaceuticals and Medical Devices Agency (PMDA)(1), Kasumigaseki 3-3-2, Chiyoda-ku, Tokyo 100-0013, Japan., Onodera H; Review Division, Pharmaceuticals and Medical Devices Agency (PMDA)(1), Kasumigaseki 3-3-2, Chiyoda-ku, Tokyo 100-0013, Japan.
Publikováno v: Regulatory toxicology and pharmacology : RTP [Regul Toxicol Pharmacol] 2017 Dec; Vol. 91, pp. 29-38. Date of Electronic Publication: 2017 Sep 06.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje